A multi-target stool-based DNA test for colorectal cancer that has become commercially popular offers promise as a complement to colonoscopic evaluations for patients with ulcerative colitis (UC) and Crohn’s disease (CD). The study was led by Mount Sinai and the Mayo Clinic.